Literature DB >> 996201

Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment.

D H Wiles, T Kolakowska, A S McNeilly, B M Mandelbrote, M G Gelder.   

Abstract

Seventeen acute psychotic patients were studied in the course of chlorpromazine (CPZ) treatment. Blood samples were taken weekly both before and two hours after the morning CPZ dose. Plasma levels of CPZ, CPZ sulphoxide (CPZ SO) monodesmethylated CPZ (NOR1CPZ) and 7-hydroxy CPZ (7OH CPZ) were estimated by gas chromatography. Plasma prolactin, luteinizing hormone, testosterone and oestrogens were measured by radioimmunoassay. Six of the seven patients who showed no clinical improvement had plasma CPZ levels equal to or higher than those of patients who improved. 'Non-responders' has a greater proportion of CPZ SO in pre-dosage samples. The occurrence of parkinsonian side effects was associated with a mean plasma CPZ of greater than 50 ng/ml and a mean plasma prolactin of greater than 30 ng/ml two hours after dosage. The elevation of prolactin preceded the onset of parkinsonian symptoms by 1-2 weeks. There was a significant positive correlation between mean plasma prolactin and mean plasma CPZ levels. The prolactin response may prove a useful index of the central antidopaminergic effect of neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 996201     DOI: 10.1017/s0033291700015841

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  14 in total

Review 1.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

3.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.

Authors:  D H Wiles; M G Gelder
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

5.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Chlorpromazine levels in plasma and milk of nursing mothers.

Authors:  D H Wiles; M W Orr; T Kolakowska
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

7.  Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to chlorpromazine challenge.

Authors:  T Kolakowska; S Fraser; M Franklin; J Knox
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.

Authors:  A Pietzcker; A Poppenberg; J Schley; B Müller-Oerlinghausen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1981

9.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

10.  Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate.

Authors:  A Jørgensen; J Andersen; N Bjørndal; S J Dencker; L Lundin; U Malm
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.